Henley

Henley Bio is a longevity-focused biotechnology company and venture studio dedicated to developing therapeutics that target the fundamental hallmarks of aging. The company operates by identifying high-impact research in the longevity space and translating it into clinical-stage programs through a decentralized and collaborative model. Their portfolio focuses on areas such as cellular senescence, epigenetic reprogramming, and mitochondrial health to extend human healthspan. By leveraging a network of leading scientists and specialized drug development expertise, Henley Bio aims to create a pipeline of first-in-class medicines for age-related pathologies.